Neuroderm, A Mitsubishi Tanabe Pharma Group Company

Neuroderm, A Mitsubishi Tanabe Pharma Group Company company information, Employees & Contact Information

NeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration. By developing next-generation drug-device combination solutions for central nervous system disorders, we aspire to make a meaningful difference in patients’ lives and drive future healthcare connectivity. Our mission is to address the challenges of the future healthcare and wellbeing ecosystem. We are passionately driven to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies.

Company Details

Employees
170
Founded
-
Address
3 Pekeris Street, Rehovot,7670212,israel
Phone
+972 8-946-2729
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
professionals..
HQ
Rehovot
Looking for a particular Neuroderm, A Mitsubishi Tanabe Pharma Group Company employee's phone or email?

Neuroderm, A Mitsubishi Tanabe Pharma Group Company Questions

News

NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations - PR Newswire

NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations PR Newswire

Parkinson Therapy ND0612 Receives Complete Response Letter - NeurologyLive

Parkinson Therapy ND0612 Receives Complete Response Letter NeurologyLive

AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24 - BioSpace

AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24 BioSpace

NeuroDerm Enters Definitive Agreement to be Acquired by - GlobeNewswire

NeuroDerm Enters Definitive Agreement to be Acquired by GlobeNewswire

AAN 2024: AbbVie and NeuroDerm highlight benefits of levodopa infusions in hope of US launch - Clinical Trials Arena

AAN 2024: AbbVie and NeuroDerm highlight benefits of levodopa infusions in hope of US launch Clinical Trials Arena

Mitsubishi unit buys Israel’s NeuroDerm - ACS Publications

Mitsubishi unit buys Israel’s NeuroDerm ACS Publications

Mitsubishi Tanabe Buys NeuroDerm for $1.1 Bilion - CHEManager

Mitsubishi Tanabe Buys NeuroDerm for $1.1 Bilion CHEManager

Mitsubishi Tanabe to acquire NeuroDerm for $1.1B - BioPharma Dive

Mitsubishi Tanabe to acquire NeuroDerm for $1.1B BioPharma Dive

Mitsubishi Tanabe buys up NeuroDerm in $1.1B deal - Fierce Biotech

Mitsubishi Tanabe buys up NeuroDerm in $1.1B deal Fierce Biotech

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy - PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy PMLiVE

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future - Nature

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future Nature

Mitsubishi Tanabe Pharma to Buy Israel's Neuroderm for $1.1 Billion - Fortune

Mitsubishi Tanabe Pharma to Buy Israel's Neuroderm for $1.1 Billion Fortune

Israeli drug maker NeuroDerm sold to Japanese pharma giant for $1.1b - The Times of Israel

Israeli drug maker NeuroDerm sold to Japanese pharma giant for $1.1b The Times of Israel

Israel’s NeuroDerm to be sold for $1.1 billion - Unpacked

Israel’s NeuroDerm to be sold for $1.1 billion Unpacked

Patent update: Neuroderm improves the design for its wearable anti-Parkinson’s infusion pump - BioWorld MedTech

Patent update: Neuroderm improves the design for its wearable anti-Parkinson’s infusion pump BioWorld MedTech

Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm - CTech

Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm CTech

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease - PR Newswire

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease PR Newswire

ND0612 Reduces OFF Time for Motor Fluctuations in Parkinson Disease at 12 Months - NeurologyLive

ND0612 Reduces OFF Time for Motor Fluctuations in Parkinson Disease at 12 Months NeurologyLive

NeuroDerm's minipump passes the patient test - Fierce Biotech

NeuroDerm's minipump passes the patient test Fierce Biotech

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations - PR Newswire

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations PR Newswire

Israeli Medi Tech Firm NeuroDerm Sold to Japanese Firm for Whopping $1.1 Billion - Haaretz

Israeli Medi Tech Firm NeuroDerm Sold to Japanese Firm for Whopping $1.1 Billion Haaretz

Phase 3 Parkinson's Trial Design of NeuroDerm's ND0612 Gets EMA Nod - Parkinson's News Today

Phase 3 Parkinson's Trial Design of NeuroDerm's ND0612 Gets EMA Nod Parkinson's News Today

NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial - Fierce Pharma

NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial Fierce Pharma

The $1 billion Israeli technology to help regulate Parkinson’s disease - The Jerusalem Post

The $1 billion Israeli technology to help regulate Parkinson’s disease The Jerusalem Post

Mitsubishi Tanabe Pharma to Buy Israel-Based NeuroDerm for $1.1 Billion - CTech

Mitsubishi Tanabe Pharma to Buy Israel-Based NeuroDerm for $1.1 Billion CTech

Israeli pharma co NeuroDerm sold for $1.1b - Globes - Israel Business News

Israeli pharma co NeuroDerm sold for $1.1b Globes - Israel Business News

NeuroDerm sold for $1.1B in Israeli pharma industry's largest deal - ישראל היום

NeuroDerm sold for $1.1B in Israeli pharma industry's largest deal ישראל היום

Top Neuroderm, A Mitsubishi Tanabe Pharma Group Company Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant